Novavax supplier to India Serum Institute for Covid vaccine |
Indian drugmaker Novavax Inc on Wednesday said that it has entered into a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate. The deal was signed on the 30th of July. The drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the; Pandemic period. in all countries other than those designated by the World Bank as upper-middle or high-income countries. On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial by late September.
|
|
|
|